On September 11, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that George Yeh, President of TLC, will be discussing recent activities regarding the company in a fireside chat with Kristen Kluska, Research Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00am ET (Press release, Taiwan Liposome Company, SEP 11, 2020, View Source [SID1234565022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 30-minute fireside chat will be a Q&A session in which Mr. Yeh will introduce TLC and talk about the company’s leading programs: TLC599 for sustained relief of osteoarthritis pain and TLC590 for sustained relief of postsurgical pain, and introduce TLC19 for prevention and treatment of COVID-19.

A recording of the fireside chat will be available on the company’s website at www.tlcbio.com in the Investors section, under News & Events.